Data From Phase 2 ACE Study of Ambit Biosciences's Quizartinib in...

In the study, quizartinib was administered orally, once a day, in 28-day treatment cycles until disease progression, elective hematopoietic stem cell transplantation or unacceptable toxicity.

http://www.biospace.com/news_story.aspx?StoryID=301184&full=1